Asia
Lonza Group Delivers Strong Performance in Q1
Lonza Group (SGX:O6Z) delivered strong contract development and manufacturing organization (CDMO) growth during the first quarter of the year, according to a Friday filing with the Singapore Exchange.The Swiss pharmaceutical company expects stronger sales in the first half of 2026 compared to the second half, backed by a lower prior-year base and planned site shutdowns.The momentum in Q1 was led by strong contributions from the integrated biologics segment and improvement from the specialized modalities segment.Lonza projects sales growth of 11% to 12% at constant exchange rates for the full year 2026.Over the medium term, the dual-listed group targets average sales growth in the low teens at constant exchange rates.
SGX:O6Z
